PRECISE-AD Study: Trying a new treatment for Early Alzheimer's disease.
The PRECISE-AD study is a phase 1 clinical trial, sponsored by ProMis Neurosciences, for people with mild cognitive impairment (MCI) to mild dementia due to Alzheimer's disease. It tests a new antibody treatment (PMN310), given by IV, that is designed to help slow down the disease. PMN310 is investigational and not yet approved by the FDA.
Eligibility Criteria
Study goal and designAdvancing precision medicine in early Alzheimer's disease
The PRECISE-AD study is testing a new IV treatment called PMN310 in people with early Alzheimer's. It looks at whether the drug is safe, well-tolerated, how it works in the body, and whether it might help slow the disease by targeting amyloid-beta.
Study-related care and supportComprehensive medical oversight and biomarker analysis
While contributing to research, participants receive:
- The possibility to receive PMN310 investigational study medication
- Advanced biomarker testing and brain imaging
- Regular cognitive assessments and memory evaluations
- Study visits with qualified medical professionals
All medical and travel costs related to the study are covered.
Volunteer journeyA structured research experience
1 - Express your interest: Answer a questionnaire to check preliminary criteria.
2 - Meet the study team: Complete a detailed brain and memory evaluation.
3 - Begin treatment (or placebo): Receive PMN310 or placebo by IV infusion once every 4 weeks, for a total of 12 infusions over 1 year.
4 - Continue the study : Be monitored during follow-up visits, and get health check-ups to observe any changes in cognition.
Join the PRECISE-AD study
Contribute to progress, support research, help others, and care for your health.
Participate in the study